Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Geropharm Insulin Aspart vs NovoRapid in Healthy Subjects
NCT04184466Phase 1Completed
- Sponsor
- Geropharm
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart biosimilar GP40071 in diabetes mellitus (DM) (2 arms), sponsored by Geropharm. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration and Maximum Observed Plasma Concentration. Started Oct 2018; status: completed.
02
Drugs
insulin aspart biosimilar GP40071
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT04184466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184466.